Compare TWI & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWI | BCYC |
|---|---|---|
| Founded | 1890 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 500.1M | 438.4M |
| IPO Year | 1993 | 2019 |
| Metric | TWI | BCYC |
|---|---|---|
| Price | $8.17 | $7.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | $11.50 | ★ $18.73 |
| AVG Volume (30 Days) | ★ 581.2K | 303.4K |
| Earning Date | 11-06-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,801,577,000.00 | $28,339,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.57 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.93 | $6.03 |
| 52 Week High | $10.94 | $21.50 |
| Indicator | TWI | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 55.37 | 50.72 |
| Support Level | $7.82 | $6.76 |
| Resistance Level | $8.90 | $7.46 |
| Average True Range (ATR) | 0.33 | 0.41 |
| MACD | 0.05 | 0.09 |
| Stochastic Oscillator | 59.92 | 60.00 |
Titan International Inc is a manufacturer of wheels, tires, wheel and tire assemblies, and undercarriage systems and components for off-highway vehicles. The company operates through three segments namely Agricultural, Earthmoving/Construction, and Consumer. Geographically, business of the group can be seen in the United States, Europe / CIS, Latin America and Other international. Titan derives majority of the revenue from Agricultural segment which manufacture various agricultural equipment, including tractors, combines, plows, planters and irrigation equipment, and are sold directly to original equipment manufacturers and to the aftermarket through independent distributors, equipment dealers and Titan's own distribution centers.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.